S
Steven Joniau
Researcher at Katholieke Universiteit Leuven
Publications - 529
Citations - 28451
Steven Joniau is an academic researcher from Katholieke Universiteit Leuven. The author has contributed to research in topics: Prostate cancer & Prostatectomy. The author has an hindex of 64, co-authored 479 publications receiving 24626 citations. Previous affiliations of Steven Joniau include Catholic University of Leuven & The Catholic University of America.
Papers
More filters
Journal ArticleDOI
EAU guidelines on prostate cancer
Axel Heidenreich,Gunnar Aus,Michel Bolla,Steven Joniau,Vsevolod Matveev,Hans Schmid,F. Zattoni +6 more
TL;DR: The guidelines have been updated and level of evidence/grade of recommendation added to the text enables readers to better understand the quality of the data forming the basis of the recommendations.
Journal ArticleDOI
EAU–ESTRO–SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent
Nicolas Mottet,Joaquim Bellmunt,Michel Bolla,Erik Briers,Marcus G. Cumberbatch,Maria De Santis,Nicola Fossati,Tobias Gross,Ann Henry,Steven Joniau,Thomas B. Lam,Thomas B. Lam,Malcolm David Mason,Vsevolod Matveev,Paul C. Moldovan,Roderick C.N. van den Bergh,Thomas Van den Broeck,Henk G. van der Poel,Theo H. van der Kwast,Olivier Rouvière,Ivo G. Schoots,Thomas Wiegel,Philip Cornford +22 more
TL;DR: The 2016 EAU-STRO-IOG Prostate Cancer (PCa) Guidelines present updated information on the diagnosis, and treatment of clinically localised prostate cancer and reflect the multidisciplinary nature of PCa management.
Journal ArticleDOI
EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent—Update 2013
Axel Heidenreich,Patrick J. Bastian,Joaquim Bellmunt,Michel Bolla,Steven Joniau,Theodor van der Kwast,Malcolm David Mason,Vsevolod Matveev,Thomas Wiegel,Filiberto Zattoni,Nicolas Mottet +10 more
TL;DR: Current evidence is insufficient to warrant widespread population-based screening by prostate-specific antigen (PSA) for PCa, and watchful waiting is a treatment alternative to androgen-deprivation therapy (ADT), with equivalent oncologic efficacy.
Journal ArticleDOI
EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer ☆
Nicolas Mottet,Joaquim Bellmunt,Michel Bolla,Steven Joniau,Malcolm David Mason,Vsevolod Matveev,Hans-Peter Schmid,Theo van der Kwast,Thomas Wiegel,Filiberto Zattoni,Axel Heidenreich +10 more
TL;DR: A summary of the 2010 version of the EAU guidelines on the treatment of advanced, relapsing, and castration-resistant prostate cancer (CRPC) summarise the most recent findings and put them into clinical practice.
Journal ArticleDOI
EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease.
Axel Heidenreich,Joaquim Bellmunt,Michel Bolla,Steven Joniau,Malcolm David Mason,Vsevolod Matveev,Nicolas Mottet,Hans-Peter Schmid,Theo van der Kwast,Thomas Wiegel,F. Zattoni +10 more
TL;DR: Current evidence is insufficient to warrant widespread population-based screening by prostate-specific antigen (PSA) for PCa, and these EAU guidelines on PCa summarise the most recent findings and put them into clinical practice.